Cargando…

Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma

Objective: The stratification of neuroblastoma (NBL) prognosis remains difficult. RNA-based signatures might be able to predict prognosis, but independent cross-platform validation is still rare. Methods: RNA-Seq-based profiles from NBL patients were acquired and then analyzed. The RNA-Seq prognosti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jian-Guo, Liang, Bo, Jin, Su-Han, Liao, Hui-Ling, Du, Guo-Bo, Cheng, Long, Ma, Hu, Gaipl, Udo S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904333/
https://www.ncbi.nlm.nih.gov/pubmed/31867276
http://dx.doi.org/10.3389/fonc.2019.01361
_version_ 1783477982437834752
author Zhou, Jian-Guo
Liang, Bo
Jin, Su-Han
Liao, Hui-Ling
Du, Guo-Bo
Cheng, Long
Ma, Hu
Gaipl, Udo S.
author_facet Zhou, Jian-Guo
Liang, Bo
Jin, Su-Han
Liao, Hui-Ling
Du, Guo-Bo
Cheng, Long
Ma, Hu
Gaipl, Udo S.
author_sort Zhou, Jian-Guo
collection PubMed
description Objective: The stratification of neuroblastoma (NBL) prognosis remains difficult. RNA-based signatures might be able to predict prognosis, but independent cross-platform validation is still rare. Methods: RNA-Seq-based profiles from NBL patients were acquired and then analyzed. The RNA-Seq prognostic index (RPI) and the clinically adjusted RPI (RCPI) were successively established in the training cohort (TARGET-NBL) and then verified in the validation cohort (GSE62564). Survival prediction was assessed using a time-dependent receiver operating characteristic (ROC) curve and area under the ROC curve (AUC). Functional enrichment analysis of the genes was conducted using bioinformatics methods. Results: In the training cohort, 10 gene pairs were eventually integrated into the RPI. In both cohorts, the high-risk group had poor overall survival (OS) (P < 0.001 and P < 0.001, respectively) and favorable event-free survival (EFS) (P = 0.00032 and P = 0.06, respectively). ROC curve analysis also showed that the RPI predicted OS (60 month AUC values of 0.718 and 0.593, respectively) and EFS (60 month AUC values of 0.627 and 0.852, respectively) well in both the training and validation cohorts. Clinicopathological indicators associated with prognosis in the univariate and multivariate regression analyses were identified and added to the RPI to form the RCPI. The RCPI was also used to divide populations into different risk groups, and the high-risk group had poor OS (P < 0.001 and P < 0.001, respectively) and EFS (P < 0.05 and P < 0.05, respectively). Finally, the RCPI had higher accuracy than the RPI for the prediction of OS (60 month AUC values of 0.730 and 0.852, respectively) and EFS (60 month AUC values of 0.663 and 0.763, respectively) in both the training and validation cohorts. Moreover, these differentially expressed genes may be involved in certain NBL-related events. Conclusions: The RCPI could reliably categorize NBL patients based on different risks of death.
format Online
Article
Text
id pubmed-6904333
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-69043332019-12-20 Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma Zhou, Jian-Guo Liang, Bo Jin, Su-Han Liao, Hui-Ling Du, Guo-Bo Cheng, Long Ma, Hu Gaipl, Udo S. Front Oncol Oncology Objective: The stratification of neuroblastoma (NBL) prognosis remains difficult. RNA-based signatures might be able to predict prognosis, but independent cross-platform validation is still rare. Methods: RNA-Seq-based profiles from NBL patients were acquired and then analyzed. The RNA-Seq prognostic index (RPI) and the clinically adjusted RPI (RCPI) were successively established in the training cohort (TARGET-NBL) and then verified in the validation cohort (GSE62564). Survival prediction was assessed using a time-dependent receiver operating characteristic (ROC) curve and area under the ROC curve (AUC). Functional enrichment analysis of the genes was conducted using bioinformatics methods. Results: In the training cohort, 10 gene pairs were eventually integrated into the RPI. In both cohorts, the high-risk group had poor overall survival (OS) (P < 0.001 and P < 0.001, respectively) and favorable event-free survival (EFS) (P = 0.00032 and P = 0.06, respectively). ROC curve analysis also showed that the RPI predicted OS (60 month AUC values of 0.718 and 0.593, respectively) and EFS (60 month AUC values of 0.627 and 0.852, respectively) well in both the training and validation cohorts. Clinicopathological indicators associated with prognosis in the univariate and multivariate regression analyses were identified and added to the RPI to form the RCPI. The RCPI was also used to divide populations into different risk groups, and the high-risk group had poor OS (P < 0.001 and P < 0.001, respectively) and EFS (P < 0.05 and P < 0.05, respectively). Finally, the RCPI had higher accuracy than the RPI for the prediction of OS (60 month AUC values of 0.730 and 0.852, respectively) and EFS (60 month AUC values of 0.663 and 0.763, respectively) in both the training and validation cohorts. Moreover, these differentially expressed genes may be involved in certain NBL-related events. Conclusions: The RCPI could reliably categorize NBL patients based on different risks of death. Frontiers Media S.A. 2019-12-04 /pmc/articles/PMC6904333/ /pubmed/31867276 http://dx.doi.org/10.3389/fonc.2019.01361 Text en Copyright © 2019 Zhou, Liang, Jin, Liao, Du, Cheng, Ma and Gaipl. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhou, Jian-Guo
Liang, Bo
Jin, Su-Han
Liao, Hui-Ling
Du, Guo-Bo
Cheng, Long
Ma, Hu
Gaipl, Udo S.
Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma
title Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma
title_full Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma
title_fullStr Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma
title_full_unstemmed Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma
title_short Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma
title_sort development and validation of an rna-seq-based prognostic signature in neuroblastoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904333/
https://www.ncbi.nlm.nih.gov/pubmed/31867276
http://dx.doi.org/10.3389/fonc.2019.01361
work_keys_str_mv AT zhoujianguo developmentandvalidationofanrnaseqbasedprognosticsignatureinneuroblastoma
AT liangbo developmentandvalidationofanrnaseqbasedprognosticsignatureinneuroblastoma
AT jinsuhan developmentandvalidationofanrnaseqbasedprognosticsignatureinneuroblastoma
AT liaohuiling developmentandvalidationofanrnaseqbasedprognosticsignatureinneuroblastoma
AT duguobo developmentandvalidationofanrnaseqbasedprognosticsignatureinneuroblastoma
AT chenglong developmentandvalidationofanrnaseqbasedprognosticsignatureinneuroblastoma
AT mahu developmentandvalidationofanrnaseqbasedprognosticsignatureinneuroblastoma
AT gaipludos developmentandvalidationofanrnaseqbasedprognosticsignatureinneuroblastoma